Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Verastem Oncology submits NDA to US FDA for avutometinib plus defactinib to treat recurrent KRAS mutant low-grade serous ovarian cancer: Boston Monday, November 4, 2024, 14:00 Hrs ...

we anticipate completing our NDA submission with the mature data from the RAMP 201 trial and discussing with the FDA a path ...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...

and for patients with KRAS wild-type (wt) LGSOC the confirmed ORR was 17% (9/52; 95% CI: 8-30). The median duration of response (DOR) was 31.1 months (95% CI: 14.8-31.1) in all evaluable patients ...

Third-line treatment with panitumumab alone or irinotecan plus cetuximab is reserved to those patients with KRAS wild-type tumors previously untreated with the anti-EGFR antibody. Whenever the ...

including with respect to KRAS wild type LGSOC; that our product candidates may experience manufacturing or supply interruptions or failures; that any of our third party contract research ...

The results also suggest that when a patient's pancreatic cancer loses the normal KRAS gene, the cancer becomes more sensitive to a type of drug called MEK inhibitors. This means that patients ...

Furthermore, the unmet need in the market, particularly for KRAS mutant and wild-type patients, underscores potential use even with limited approval. The longer duration of therapy for mutant ...

The multicenter, single-arm, registrational, tumor-agnostic Phase 2 trial is assessing rezatapopt as monotherapy at a dose of 2000 mg once-daily in patients with TP53 Y220C and KRAS wild-type advanced ...

Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...